Novan (NOVN) rises on new nitric oxide data study by a nobel prize-winning scientist, right now the stock is up 20% since last week and continues to climb.
Although the recent study “Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19” by Ackermann, et al does not include any mention of nitric oxide, many of the world’s leading researchers and scientists agree that there are clear implications and correlations regarding nitric oxide as a viable treatment for COVID-19.
The study was conducted by an international team of medical scientists who compared the lungs of patients who died from COVID-19 with lungs of patients who died from influenza as well as healthy lungs donated for transplantation. These researchers discovered an unexpected disease pattern in COVID-19 lungs: The virus invades the cells that line blood vessels, called endothelial cells, and this was accompanied by blood clots.
Compared to the flu, COVID-19 lungs had 9-fold more blood clots and the blood vessels were injured by the virus, causing an unusual reaction of blood vessel growth.
Louis J. Ignarro, PhD, Nobel Prize-Winning Scientist and UCLA Distinguished Professor Emeritus, explains the significance the results of this study have on nitric oxide as treatment for COVID-19.
“Basically, this study shows that the coronavirus causes destruction of the capacity of blood vessels in the lungs to produce nitric oxide (NO). The virus destroys the vascular endothelial cells (the name for the cells that line blood vessels), which are the cells that produce NO. When NO is deficient, the result is increased blood clotting or thrombosis. The study reveals that the lungs from patients who died from COVID-19 are characterized by tiny blood clots in the lungs, which led to tissue inflammation, destruction, and pneumonia,” says Ignarro.
Novan Inc. (NOVN) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Novan Inc.’s current insider ownership accounts for 0.70%, in contrast to 17.40% institutional ownership. According to the most recent insider trade that took place on Jul 02, this organization’s 10% Owner sold 6,287 shares at the rate of 2.75, making the entire transaction reach 17,289 in total value, affecting insider ownership by 2,598,485. Preceding that transaction, on Jul 01, Company’s 10% Owner sold 913 for 2.74, making the whole transaction’s value amount to 2,502. This particular insider is now the holder of 2,604,772 in total.
Should you buy Novan (NOVN) stock?
Shares of these Novan, overall, appear to be a very good investment option, with Wall Street analysts expecting its price to rise considerably in the next several years. The majority of the metrics point to this investment being highly attractive.
